Quick Answer
GT Biopharma, Inc. reported Total Revenue of $0.00 for fiscal year 2020.
GT Biopharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $0.00 |
| Net Income | -$28.35M -115.4% |
-$13.16M -73.3% |
-$7.60M +63.6% |
-$20.88M +64.0% |
-$58.01M -105.0% |
-$28.30M +26.8% |
| Diluted EPS | -$6.68 +3.7% |
-$6.94 -23.0% |
-$5.64 +71.3% |
-$19.66 | — | — |
| Total Assets | $7.12M +68.3% |
$4.23M -70.0% |
$14.11M -15.7% |
$16.74M -48.0% |
$32.17M +468.3% |
$5.66M +1329.5% |
| Cash and Equivalents | $6.81M +72.4% |
$3.95M +266.2% |
$1.08M -81.0% |
$5.67M -36.8% |
$8.97M +69.3% |
$5.30M +18817.9% |
| Stockholders Equity | -$25.88M -1449.4% |
-$1.67M -122.3% |
$7.48M -36.3% |
$11.73M -46.4% |
$21.91M +179.7% |
-$27.50M -42.4% |
| R&D Expense | $3.47M -40.1% |
$5.80M -10.3% |
$6.47M -26.6% |
$8.81M -8.1% |
$9.59M +1877.5% |
$485.0K -70.9% |
| Operating Income | -$12.42M +13.5% |
-$14.36M -5.8% |
-$13.58M +36.1% |
-$21.26M +63.0% |
-$57.52M -750.3% |
-$6.76M -142.1% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 25.53M +1042.8% |
2.23M +61.8% |
1.38M +26.6% |
1.09M -96.6% |
32.06M +514.4% |
5.22M +27.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2021 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$3.11M | +8.7% | -117.3% |
| Diluted EPS | September 30, 2025 | -$0.83 | +45.8% | -50.9% |
| Total Assets | September 30, 2024 | $6.76M | -58.1% | -27.1% |
| Cash and Equivalents | September 30, 2025 | $2.53M | -60.6% | -51.6% |
| Stockholders Equity | September 30, 2025 | $3.00M | +43.1% | +4.9% |
| R&D Expense | September 30, 2025 | $634.0K | -51.5% | +74.7% |
| Operating Income | September 30, 2025 | -$3.38M | +6.2% | -123.5% |
| Gross Profit | March 31, 2020 | $0.00 | — | — |
| Shares Outstanding | September 30, 2025 | 6.05M | +170.9% | +84.9% |
- GT Biopharma, Inc. reported Total Revenue of $0.00 for fiscal year 2020.
- GT Biopharma, Inc. reported Net Income of -$28.35 million for fiscal year 2025.
- GT Biopharma, Inc. showed a decrease of -115.4% in Net Income compared to the prior fiscal year.
- GT Biopharma, Inc. reported Diluted EPS of $6.68 per share (loss) for fiscal year 2025.
- GT Biopharma, Inc. showed an increase of +3.7% in Diluted EPS compared to the prior fiscal year.
- GT Biopharma, Inc. reported Total Assets of $8.11 million for fiscal year 2025.
- GT Biopharma, Inc. showed an increase of +87.6% in Total Assets compared to the prior fiscal year.
- GT Biopharma, Inc. reported Cash and Equivalents of $6.81 million for fiscal year 2025.
- GT Biopharma, Inc. showed an increase of +72.4% in Cash and Equivalents compared to the prior fiscal year.
- GT Biopharma, Inc. reported Stockholders Equity of $5.79 million for fiscal year 2025.
- GT Biopharma, Inc. showed an increase of +92.9% in Stockholders Equity compared to the prior fiscal year.
- GT Biopharma, Inc. reported R&D Expense of $3.47 million for fiscal year 2025.
- GT Biopharma, Inc. showed a decrease of -40.1% in R&D Expense compared to the prior fiscal year.
- GT Biopharma, Inc. reported Operating Income of -$12.42 million for fiscal year 2025.
- GT Biopharma, Inc. showed an increase of +13.5% in Operating Income compared to the prior fiscal year.
- GT Biopharma, Inc. reported Gross Profit of $0.00 for fiscal year 2017.
- GT Biopharma, Inc. reported Shares Outstanding of 25.53 million shares for fiscal year 2025.
- GT Biopharma, Inc. showed an increase of +1042.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: